Skip to main content

Table 2 Pharmacokinetic parameter of tipepidine in TS-141 and Asverin group

From: Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder

TS-141 30 mg

All Phenotypes

PM

IM

EM

UM

N

29

1

2

25

1

 Cmax (ng/mL)

 

9.90 ± 11.6

57.1

24.9 ± 16.8

7.17 ± 4.66

1.06

 AUC0-∞ (ng⋅h/mL)

arithmetic mean

83.9 ± 138

728

213 ± 148

51.0 ± 35.1

4.69

geometric mean

45.9

728

185

40.3

4.69

CV (%)

164

–

69.5

68.8

–

 MRT0-∞ (h)

 

11.8 ± 4.70

17.0

9.86 ± 0.764

11.8 ± 4.93

11.0

Asverin 40 mg

All Phenotypes

PM

IM

EM

UM

N

42

1

5

35

1

 Cmax (ng/mL)

 

30.7 ± 28.5

125

58.2 ± 26.2

24.9 ± 21.6

1.05

 AUC0-∞ (ng⋅h/mL)

arithmetic mean

114 ± 177

1080

248 ± 126

70.5 ± 57.9

3.62

geometric mean

61.9

1080

220

51.6

3.62

CV (%)

155

–

50.8

82.2

–

 MRT0-∞ (h)

 

4.67 ± 1.67

12.3

5.76 ± 0.578

4.33 ± 1.13

3.54

  1. PM Poor metabolizer, IM Intermediate metabolizer, EM Extensive metabolizer, UM Ultrarapid metabolizer